One cancer target of significant interest, a non-receptor protein tyrosine phosphatase (PTP) known as Src Homology 2 domain-containing protein tyrosine phosphatase (SHP2), is one of these ...

Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

SHP2 has become a popular target among cancer drug developers, as it lies upstream of other molecular pinch points, like RAS/ERK MAPK which drive cellular proliferation and survival.